Recent Updates
Recently added Catalysts

Imsidolimab

NDA/BLA

Generalized Pustular Psoriasis | Biologics | Dermatology |Vanda Pharmaceuticals Inc.|Trials Updated: Mar 17, 2026

Imsidolimab development status

Highest phase NDA/BLA
Registered trials 6 across 1 sponsor since Aug 2018

Imsidolimab target and mechanism

Molecular targetIL1RL2, IL1RAP
Target classAntagonist
ModalityBiologics

Also known as ANB019

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials5
Total Enrollment384

FDA Designations

ORPHAN_DRUG

Imsidolimab clinical trials

Imsidolimab · 5 trials · 4 indications

Phase 3 1Phase 2 4
NCT05352893Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPGeneralized Pustular Psoriasis
COMPLETED45 Analytics
PHASE3COMPLETED
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
Generalized Pustular PsoriasisUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear)
Week 4

The Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA) is a physician-based assessment of the overall disease severity of GPP at the time of evaluation (specifically pustules, erythema, and scaling/crusting of pustular psoriasis lesions). The GPPPGA is graded on a 5-point scale, ranging from 0 (clear) to 4 (severe). GPPPGA Scale: 0 = Clear, 1 = Almost clear, 2 = Mild, 3 = Moderate, 4 = Severe.

Change From Baseline in AN Count at Week 16: Placebo-Controlled Period
Baseline, Week 16

The AN count was defined as the sum of the number of abscesses and inflammatory nodules from all locations.

Change From Baseline in Facial Inflammatory Lesion Counts at Week 12
Baseline, Week 12

The number of facial inflammatory lesions (pustules, papules, and nodular lesions) on the forehead, left and right cheeks, nose, and chin were counted. Baseline was defined as the last available measurement taken prior to the first dose of study treatment.

Change From Baseline in Palmoplantar Pustulosis Psoriasis Area Severity Index (PPPASI)
Baseline to Week 16

The Palmoplantar Pustulosis Area and Severity Index (PPPASI) is used to assess the severity of palmoplantar pustulosis lesions and their response to therapy. The glabrous skin of both palms and both soles are assessed for erythema, pustules, and desquamation (scaling), each on a scale from 0 (none) to 4 (very severe). The area affected of each palm and sole is scored from 0 (0%) to 6 (90-100%). Scores for the 3 characteristics of PPP are summed and adjusted for the area affected, and the scores for each palm and sole are added to calculate the total score. The PPPASI total score ranges from 0 to 72. A higher score indicates more severe disease, and a negative change from Baseline indicates improvement.

Number of Participants With Treatment-emergent Adverse Events (TEAEs)
From first dose of any study drug to Week 24

Clinical safety was evaluated by reporting incidence of adverse events up to week 24. TEAEs are defined as new events that occured during or after first dose of study drug or any event that worsens after first dose of study drug. A serious AE (SAE) is defined as any untoward medical occurrence that resulted in death, was life-threatening, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or an important medical event that may jeopardize the participant or require medical or surgical intervention to prevent one of the outcomes listed above. Severity was assessed by the Investigator as mild (easily tolerated, causing minimal discomfort and not interfering with everyday activities), moderate (causes sufficient discomfort and interferes with normal everyday activities) or severe (prevents normal everyday activities). The Investigator assessed the relationship between study treatment and each AE based on clinical judgement.

Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale
Week 4 and Week 16

Clinical response was defined as "Very much improved," "Much Improved," or "Minimally Improved" on the CGI scale according to the Modified Japanese Dermatological Association Severity Index (JDA-SI) total score. The JDA-SI includes assessment of skin lesions (area of erythema with pustules, area of erythema total, and area of edema) and fever, white blood cell count, C-reactive protein and serum albumin levels. The total score ranges from 0 to 17 (severe). CGI was assessed based on the JDA-SI according to the following: * Very Much Improved: Reduction in JDA-SI total score by 3 or \> points; * Much improved: Reduction in JDA-SI total score by 1 or 2 points; * Minimally improved: No change in JDA-SI total score and area of erythema with pustules reduced by \<20% or clinically meaningful improvement in at least 1 other component of the modified JDA-SI.

Percent Change From Baseline in Body Surface Area of Erythema With Pustules at Week 1, Week 4, and Week 16
Baseline, Week 1, Week 4, and Week 16

Excluding palms and soles from 0% to 100%. The palmar surface of one hand (using the subject's hand and including the fingers) represents 1% of his or her total BSA.

Secondary Endpoints

Percentage of Patients Achieving a PRS Score of 0 (Clear) or 1 (Almost Clear)
Week 1
Percent Change From Baseline in AN Count at Week 16: Placebo-Controlled Period
Baseline, Week 16
Number of Participants Achieving Hidradenitis Suppurativa Clinical Response 50 (HiSCR50): Placebo-Controlled Period
Week 16
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
750 mg ImsidolimabEXPERIMENTAL -
300 mg ImsidolimabEXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
Imsidolimab 400/200 milligrams (mg)EXPERIMENTAL400 milligrams (mg) of imsidolimab on Day 1 followed by 200 mg imsidolimab every 4 weeks by subcutaneous (SC) injection up to 48 weeks
Imsidolimab 200/100 mgEXPERIMENTAL400 milligrams (mg) of imsidolimab on Day 1 followed by 200 mg imsidolimab every 4 weeks by subcutaneous (SC) injection up to 48 weeks
Imsidolimab 400/200 mgEXPERIMENTALParticipants received imsidolimab 400 milligrams (mg) by subcutaneous (SC) injection on Day 1, followed by 200 mg on Days 29 and 57.
imsidolimabEXPERIMENTALParticipants will receive 200 mg imsidolimab by subcutaneous injection on Day 1 followed by monthly doses of 100 mg imsidolimab by subcutaneous injection on Days 29, 57, and 85.

Interventions

NameTypeDescription
750 mg ImsidolimabDRUGIntravenous
300 mg ImsidolimabDRUGIntravenous
PlaceboOTHERIntravenous
ImsidolimabBIOLOGICALHumanized Monoclonal Antibody
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 80 Years
SexALL
Healthy VolunteersNo
Study Sites65

Inclusion Criteria: \- Subject has a BSA affected with pustules (excluding palms and soles) ≥ 5%, a GPPPGA score ≥ 3 (moderate severity), and a PRS score ≥ 3 (moderate severity) at Day 1 Exclusion Criteria: * Subject has other form of psoriasis excluding psoriasis vulgaris * Subject flare is so s...

Countries:United StatesAustraliaFranceGeorgiaGermanyMalaysiaMoroccoPolandRomaniaSouth KoreaSpainTaiwanThailandTunisiaTurkey (Türkiye)CanadaUnited Kingdom
Unlock Eligibility Criteria

Frequently asked questions about Imsidolimab

What is imsidolimab?

Imsidolimab is an investigational monoclonal antibody being developed by Vanda Pharmaceuticals Inc. for dermatologic conditions. It is designed as an antagonist of IL1RL2 and IL1RAP and is being studied in acne vulgaris, generalized pustular psoriasis, hidradenitis suppurativa, and palmoplantar pustulosis. It has completed Phase 2 clinical trials and remains in clinical development.

What is imsidolimab used for?

Imsidolimab is being studied for several inflammatory skin conditions: generalized pustular psoriasis, hidradenitis suppurativa, acne vulgaris, and palmoplantar pustulosis. These are the indications under investigation in its clinical program. It is investigational and has not been approved for any use.

What does imsidolimab target?

Imsidolimab targets IL1RL2 and IL1RAP and acts as an antagonist. By binding these targets, the monoclonal antibody is designed to block interleukin-36 receptor signaling, a pathway involved in inflammatory skin disease. This mechanism underlies its study in pustular psoriasis and related dermatologic conditions.

Who makes imsidolimab?

Imsidolimab is developed by Vanda Pharmaceuticals Inc., which trades on Nasdaq under the ticker VNDA. Vanda is running the clinical program for the drug across multiple dermatologic indications, including generalized pustular psoriasis, hidradenitis suppurativa, acne vulgaris, and palmoplantar pustulosis.

What phase is imsidolimab in?

Imsidolimab is in clinical development. Its completed studies include Phase 2 trials in hidradenitis suppurativa, acne vulgaris, and palmoplantar pustulosis, plus a Phase 3 trial in generalized pustular psoriasis. It is investigational and has not been approved by the FDA for any indication.

What clinical trials is imsidolimab in?

Imsidolimab has completed several trials. These include NCT05352893 in generalized pustular psoriasis, NCT04856930 in hidradenitis suppurativa, NCT04856917 in acne vulgaris, and NCT03633396 in palmoplantar pustulosis. All four studies are listed as completed, and the trials together enrolled participants across North America, Europe, and Asia.